TheraRadar
Data updated: Jul 17, 2026

CIPEPOFOL · HAISCO PHARMACEUTICAL GROUP CO LTD

Approved 2026-05-29
1
Indication
--
Phase 3 Trials
0
Years on Market

Details

Status
Prescription
First Approved
2026-05-29
Routes
N/A
Dosage Forms
INJECTION

Companies

Active Ingredient: CIPEPOFOL

CIPEPOFOL Approval History

Original
New Indication
New Form
Label Update
1 FDA actions from 2026 to 2026
May 2026 ORIGINAL
New Drug · Type 1 - New Molecular Entity

What CIPEPOFOL Treats

1 FDA approvals

Originally approved for its first indication in 2026 .

  • Other (1)
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT06391931 HSK3486-310 Ph 3 completed A Multicenter, Open, Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Cipepofol Injection for General Anesthesia in Pediatric Patients Undergoing Elective Surgery
NCT06740201 HSK3486-408 Ph 4 recruiting A Study to Evaluate the Accuracy of aTCI Model of Cipepofol in Patients With General Anesthesia During Elective Surgery
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CIPEPOFOL FDA Label Details

Track CIPEPOFOL with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.